Stefanie Doebler, Partner at Covington & Burling LLP, kicked off the Pharmaceutical Compliance Congress (PCC) Hybrid Event in September 2021, with a State of the Industry Spotlight Session focused on critical bio/pharma policy updates for compliance after COVID. The session assessed the current state of bio/pharmaceutical companies post-pandemic, evaluated current healthcare policies and rebate rules impacting the industry, and helped navigate drug pricing transparency and reporting on a state and federal level. Watch the full presentation recording below.
Compliance
State of the Industry — Critical Bio/Pharma Policy Updates for Compliance After COVID | Covington
![](https://knect365.imgix.net/article/images/cacheable/502520c3-bcb2-48ac-b6be-b8e0c2d602c3-featured-de941a3cffec650ac5df6da62e055b2d.png?auto=format&fit=max)